

Bringing in the Research Dollars! (BiRD)



Presented by:
The Emory+Children's Pediatric Research Center

The monthly BiRD announcement highlights
pediatric research funding opportunities

Contact stacy.heilman@emory.edu with questions on the funding opportunities
highlighted below or for general research grant application advice

February 2012 BiRD Contents

- ❖ Collaborative [Hemoglobinopathies Research](#) Program funding opportunity
- ❖ [NIH Nutrition/Obesity Core Center](#) application and [Aetna Foundation grant](#) opportunity to research issues related to obesity, health care equity and integrated health care.
- ❖ [Cancer technology development](#) opportunity and [Cancer Pediatric Fellowship award](#)
- ❖ [Partnerships for Development of Vaccine Technologies](#) R01 and a P01 [for HIV Vaccine Research & Design](#)
- ❖ Potential collaborative opportunities with GA Tech to pursue research [modeling social behavior](#) and towards utilizing [Mobile Health tools to improve patient-provider education and chronic disease self-management](#)
- ❖ HRSA opportunity for applied research to [assess effectiveness of maternal, infant and early childhood home visiting services](#)
- ❖ Availability of intramural research seed funds specifically for the [Pediatric Research Centers](#), seed funds for the [Healthcare Innovation Program](#) and from GRA for [life science technology commercialization](#)
- ❖ [March of Dimes career development](#) award program
- ❖ ACTSI sponsored [KL2](#) program announcement and [Masters of Science in Clinical Research](#) program description

Other announcements

- ❖ [Submit autism research ideas](#) for future focus to Autism Speaks
- ❖ [Summer student research](#) opportunity in oncology

GENERAL FEDERAL/COLLABORATIVE POTENTIAL

Program/Link **Excellence in Hemoglobinopathies Research Award (EHRA) (U54)**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-13-005.html>

Purpose	The purpose of this U54 program issued by the National Heart, Lung, and Blood Institute (NHLBI) is to encourage interdisciplinary approaches and support the development of studies that will accelerate high-impact multi-disciplinary basic and translational research in the hemoglobinopathies and facilitate maximal collaborations among basic and translational scientists and clinical hematologists located throughout the US or at international sites. <i>Each application must propose a single project</i> that approaches a common scientific theme through innovative collaborations among investigators in two or more relevant disciplines, providing opportunities for research which will translate basic observations to applied clinical research. The proposed project should focus on the development of a specific discovery or deliverable (e.g., small molecules, biologics, biomarkers, and other methodologies) to be used in the diagnosis or treatment of sickle cell disease or the thalassemias. The focus of this funding initiative is basic research and early translational trials involving small numbers of patients.
Funds Avail	Application budgets are not limited, but need to reflect actual needs of the proposed project. Project duration of up to 5 years may be requested.
Deadline	May 8, 2012
Remarks	➤ Applicants will be required to propose research that will, by the end of the project period, develop candidate potentially therapeutic molecules, biomarkers, or imaging modalities. Because the focus is basic research and early translational trials involving small numbers of patients, this RFA is unlikely to provide support for novel therapeutic approaches already being tested in patients. ➤ Research teams are not required to have prior collaborative experience but must be able to demonstrate an integrated, practical approach that will result in the effective progression of mechanistic/basic concepts toward application in the clinic. Either multiple PI's or one PI with co-investigators is permitted. ➤ Groups of interested investigators have already begun to discuss strategies for developing competitive responses to this RFA. To facilitate this process, The Emory+Children's Research office will hold an open forum in mid-March. The purpose of the forum will be the following: i. To provide investigators an opportunity to get feedback about well-developed proposed projects from a group of senior investigators, ii. To allow investigators interested in SCD to learn about ongoing and proposed research initiatives in this area, and iii. To provide an opportunity for junior faculty and trainees to learn more about the scope and logistics of developing such an application.

If you are interested in learning more about these plans, would like help in

finding a suitable collaborator and/or wish to inquire about submitting a proposal for the March presentation, please contact Stacy Heilman at stacy.heilman@emory.edu I can also help in identifying other possible SCD funding mechanisms.

Program/Link	Modeling Social Behavior (R01) http://grants.nih.gov/grants/guide/rfa-files/RFA-GM-13-006.html
Purpose	Soliciting applications for developing and testing innovative theories and computational, mathematical, or engineering approaches to deepen our understanding of complex social behavior. This research will examine phenomena at multiple scales to address the emergence of collective behaviors that arise from individual elements or parts of a system working together. This FOA will support research that explores the often complex and dynamical relationships among the parts of a system and between the system and its environment in order to understand the system as a whole. To accomplish the goals of this FOA we encourage applications that build transdisciplinary teams of scientists spanning a broad range of expertise. Minimally this team should include senior investigators with expertise in the behavioral or social sciences as well as in computational and systems thinking (computer science, mathematics, engineering, systems-level methodology). Research can involve model organisms or humans. The FOA will support small research projects focusing on theory building and testing, development and testing of innovative methods or methodological approaches, as well as small infrastructure projects focusing on development and testing of shared resources (in the context of a driving biological, basic behavioral or social, or human health issue). The FOA also will fund larger and more integrative research projects focusing on the modeling of complex social behavior.
Funds Avail	Application budgets are not limited, but need to reflect actual needs of the proposed project. The maximum period is 5 years.
Deadline	April 3, 2012
Remarks	➤ Research can involve model organisms or humans. ➤ NIMH is particularly interested in applications in response to this FOA that seek to build transdisciplinary teams that can apply appropriate modeling techniques to multidimensional social neuroscience data. ➤ Areas of research interest are not limited to but include: ○ Integration of knowledge at multiple levels and scales (including biological, behavioral, social, and environmental) to understand and alleviate health disparities

- o Spread of multiple health and/or risk behaviors within social networks (e.g., sleep; diet, nutrition, and food choice; physical activity; tobacco, alcohol, drug use, and other addictions) and use of internet-based communities and other dynamical social networks to understand principles of collective behavior and improve human health

This could be a good collaborative effort between pediatric researchers at Emory/Children's and computer scientists or engineers at GA Tech.

Program/Link	Nutrition Obesity Research Centers (P30) http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-12-004.html
Purpose	The objective of the Nutrition Obesity Research Centers program is to bring together basic science and clinical investigators from relevant disciplines to enhance and extend the effectiveness of research related to nutritional sciences and/or obesity, and related disorders, with clinical and/or translational applications in these areas. The NIDDK-supported Nutrition and Obesity Research Centers (NORC) are part of an integrated program of nutritional sciences and obesity research. The NORC program combines the previously supported NIDDK Clinical Nutrition Research Units (CNRUs) and the Obesity Nutrition Research Centers (ONRCs) into one centers program. Each proposed NORC must be organized around central themes that reflect the nutrition and/or obesity research focus of the center members.
Funds Avail	Application budgets are limited to \$750,000 direct costs, but need to reflect actual needs of the proposed Center. Project periods may not exceed 5 years.
Deadline	June 29, 2012
Remarks	➤ An existing program of excellence in biomedical basic and clinical research in the areas of nutritional sciences and/or obesity, and related disorders, is required ➤ Four to six cores are usually included in a Center application
Program/Link	Maternal, Infant, and Early Childhood Home Visiting Research Program https://grants.hrsa.gov/webExternal/FundingOppDetails.asp?FundingCycleId=3396749F-91A4-4739-B3D7-3F59030AFFC0&ViewMode=EU&GoBack=&PrintMode=&OnlineAvailabilityFlag=&pageNumber=&version=&NC=&Popup
Purpose	The MIECHV Research Program supports applied research relating to maternal, infant, and early childhood home visiting services which show promise of advancing knowledge about the implementation and effectiveness

of home visiting programs designed to improve life outcomes among mothers, infants, and young children. Findings from the research supported by the MIECHV Research Program are expected to have potential for application in improving home visiting programs for mothers and children. By legislative statute, the MIECHV Research Program requires the use of random assignment designs to the maximum extent feasible.

- Funds Avail** Requests may be up to \$300,000 per year (total costs). The project period is up to three (3) years.
- Deadline** March 16, 2012
- Remarks** ➤ It is expected that 2 grants will be awarded

Program/Link **mHealth Tools to Promote Effective Patient–Provider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R01)**
<http://grants.nih.gov/grants/guide/pa-files/PA-11-330.html>

Purpose The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient–provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress and may improve health outcomes. This announcement encourages the development, testing and comparative effective analysis of interventions utilizing mHealth technologies in underserved populations.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

Deadline Standard NIH Due Dates*

- Remarks**
- Companion RFA's include
 - R21, Exploratory/Developmental Grant - <http://grants.nih.gov/grants/guide/pa-files/PA-11-332.html>
 - R03, Small Grant Program - <http://grants.nih.gov/grants/guide/pa-files/PA-11-331.html>
 - NICHD was recently added as a participating organization in these funding mechanisms

Program/Link **Partnerships for Development of Vaccine Technologies (R01)**

<http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-014.html>

Purpose	Invites research applications for projects focused on preclinical development of candidate technologies* (including adjuvants) that would improve vaccine effectiveness and/or simplify vaccine delivery to patient populations during a natural outbreak of an infectious disease or following the intentional release of an infectious agent. Applications must include a Product Development Strategy attachment and demonstrate substantive investment** by at least one industrial participant***. Examples of research areas may include, but are not limited to: technology/platform optimization; safety evaluation; stability testing; manufacturing; product characterization; adaptation of technologies or products to biodefense applications; development of broad spectrum platforms and/or production technologies; optimization of product safety, efficacy, or delivery; process development; scale-up; and production of quantities sufficient for preclinical regulatory requirements.
Funds Avail	Budgets for direct costs of up to \$750,000 per year may be requested. In addition, applicants may request up to a total of \$300,000 for major equipment in the first year of the award to ensure that research aims can be met and biohazards can be contained.
Deadline	June 26, 2012
Remarks	➤ * For the purpose of this FOA “candidate technology” is defined as a vaccine technology for which proof-of-concept data have been obtained. ➤ ** “Substantive investment” is defined as a significant commitment of one or more resources to the project including, but not limited to: product development support/guidance, personnel, in kind contributions of materials and/or reagents (i.e. chemical libraries, innovative biotechnology platforms, scale up of GMP chemical synthesis or production, etc.), provision of animal or other laboratory models for evaluation, subcontracts, data management resources, regulatory support, or alterations/renovations of facilities or provision of equipment to address biohazard concerns. ➤ *** For the purpose of this FOA, “industrial participant” is defined as a large or small, domestic or foreign, pharmaceutical, biotechnology, bioengineering, and chemical company, or a related non-profit entity with an established track record in product development.

NOTE: This FOA states that PD(s)/PI(s) are strongly encouraged to obtain expertise in the areas of product development planning and target product profile development in general and regulatory matters in particular. Expertise may be retained as defined effort or may be included as periodic consultation on specific issues. For connection to assistance in this area, contact stacy.heilman@emory.edu

Program/Link **HIV Vaccine Research and Design (HIVRAD) Program (P01)**
<http://grants.nih.gov/grants/guide/pa-files/PA-12-087.html>

Purpose Support of multi-component, multi-disciplinary projects that address important scientific questions relevant to AIDS prophylactic vaccine discovery research. The HIVRAD program is designed to fund projects that further address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine. Applications aimed at developing or optimizing a specific vaccine platform should lay out a research pathway with clear decision points. Extensive modeling of vaccine concepts in non-human primates may be included.

Funds Avail Application budgets are not limited, but need to reflect actual needs of the proposed project. Maximum project period is 5 years.

Deadline June 13, 2012; June 13, 2013; June 13, 2014

Remarks

- Applications for five years of support should include plans that have advanced past the exploratory stage and include preliminary data. Less fully developed applications can request less than 5 years of support to establish feasibility.
- Clinical studies involving human subjects or vaccine research focused solely on therapeutic applications are not considered appropriate and will not be funded under this FOA. For information on programs that support therapeutic vaccine development, please contact program staff.

Program/Link **Early-Stage Innovative Technology Development for Cancer Research (R21)**
<http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-002.html>

Purpose This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), solicits grant applications proposing exploratory research projects focused on the inception and development of early stage, highly innovative, technologies or emerging technologies with significant transformative potential that has not yet been explored in a cancer-relevant use. An emerging technology is defined (for the purpose of this FOA) as one that has passed the initial developmental stage, but has not yet been evaluated within the context of a cancer-relevant intended use and requires significant modification for the proposed application. The emphasis of this FOA is on technologies with a high degree of technical innovation with the potential to significantly affect and transform investigations exploring the molecular and cellular bases of cancer. If successful, these technologies would accelerate and/or enhance research in the areas of cancer biology, prevention, diagnosis and treatment, control, epidemiology, and/or cancer health disparities.

Technologies proposed for development may be intended to have widespread applicability but must be based on molecular and/or cellular characterizations of cancer.

Funds Avail Direct costs are limited to \$500,000 over an R21 3-year period, with no more than \$200,000 in direct costs allowed in any single year. Application budgets must reflect actual needs of the proposed project.

Deadline February 23, 2012; May 21, 2012; September 18, 2012

Remarks **The current issuance of the IMAT Program consists of the following three areas, and comprising 4 separate RFAs:**

- **Innovative Technology Development for Cancer Research** (this FOA, [RFA-CA-12-002](#), using the R21 funding mechanism), which is intended to support research projects that are centered on the inception and preliminary development of highly innovative technologies with potentially high impact on cancer research;
- **Emerging Technology Development for Cancer Research** ([RFA-CA-12-003](#), using the R33 funding mechanism), designed to support further development (beyond the initial phase) of emerging technologies that have the potential to be transformative when used for cancer research and/or in cancer-relevant clinical care; and
- **Innovative and Applied Emerging Technologies in Biospecimen Science** ([RFA-CA-12-004](#), using the R21 funding mechanism, and [RFA-CA-12-005](#), using the R33 funding mechanism), which is centered on the development and validation of novel technologies for cancer-relevant biospecimens. The emphasis is on issues related to pre-analytical variations in the collection, processing, handling, and storage of cancer-relevant biospecimens or their derivatives to improve their quality and utility in cancer research.

FOUNDATION

Program/Link **Aetna Foundation National Program Research Grants**
<http://www.aetna-foundation.org/foundation/apply-for-a-grant/grantseeker-information/application-review-process.html>

Purpose Focus on issues that improve health and the health care system in the following three areas:

- **Obesity:** Addressing the rising rate of obesity among U.S. adults and children
- **Racial and Ethnic Health Care Equity:** Promoting equity in health and health care for common chronic conditions and infant mortality
- **Integrated Health Care:** Advancing high-quality health care by improving care coordination and communications among health care

professionals; creating informed and involved patients; and promoting cost-effective, affordable care

Research must be generalizable across the nation and have national impact and relevance.

Funds Avail Budget requests may not exceed \$250,000 total costs for a total of 2 years.

Deadline Letters of inquiry are required and are accepted on a rolling basis (If invited to apply, full proposals are accepted on Feb 15, May 15, Aug 15 and Nov 15)

Remarks ➤ Regional Grant program also offered where the impact and relevance of the proposed research is applicable to a specific region, state or community within our defined areas of geographic focus.

CAREER DEVELOPMENT/TRAINING

Program/Link **Damon Runyon-Sohn Pediatric Cancer Fellowship Award**
http://www.damonrunyon.org/for_scientists/more/pediatric_fellowship_award_overview

Purpose The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.

Funds Avail \$50,000 - 60,000 in stipend and \$2,000 in expenses annually for up to 3 years

Deadline March 15, 2012

Remarks ➤ Mentor required
➤ Candidates who have already accepted a postdoctoral research fellowship award are not eligible
➤ Postdoctoral training in the same institution in which the applicant received his/her degree is discouraged, particularly if it is in the same department
➤ Must devote 80% (level 2 funding) – 100% (level 1 funding) to research activities

Program/Link **2013 Basil O'Connor Starter Scholar Research Award Program**
http://www.marchofdimes.com/downloads/BOC_RFP_2013.pdf

Purpose This award is designed to support young scientists just embarking on their independent research careers and is limited, therefore, to those holding recent faculty appointments. The applicants' research interests should be consonant with those of the Foundation.

Funds Avail Up to \$75,000 per year, and are awarded for two years. These grants do not cover the recipient's salary, but do provide salary support for technical help.

Deadline	Letter of nomination due March 15, 2012
Remarks	➤ Deans, Chairs of Departments, or Directors of Institutes/Centers should submit nominations so please first contact Stacy Heilman if you are interested in requesting a nomination. ➤ Basil O'Connor applicants may not be recipients of a major grant (e.g., an RO1, or other grant exceeding \$200,000 a year) at the time of the application. ➤ Candidates may not simultaneously submit an application for any other March of Dimes research program. Those who have previously submitted an application to the March of Dimes are not eligible for a Basil O'Connor Award, but may apply for a regular research grant.

Program/Link **Mentored Clinical & Translational Research Scholars ACTSI KL2 Program**

<http://www.actsi.org/areas/retcd/kl2/index.html>

Purpose	Junior faculty members at the MD or PhD level from a wide variety of disciplines at Emory University, Morehouse School of Medicine, or Georgia Institute of Technology who are committed to an academic career in clinical and/or translational research and who have excellent potential to become an independent clinical investigator are encouraged to apply to the KL2 – Mentored Clinical and Translational Research Scholars (MCTRS) Program. The KL2 award provides support for didactic and mentored research training for junior faculty members committed to a career in clinical investigation.
Funds Avail	For 75% salary support, a \$25,000/ year KL2 technical budget for research costs and tuition, and some salary support for the KL2 scholar's Lead Mentor.
Deadline	March 1, 2012
Remarks	➤ KL2 award recipients must devote 75% professional effort to the program (surgeons may devote 50% effort). ➤ Partial or matching salary support from the applicant's Division, Department or other non-federal sources is highly encouraged but not required. ➤ Mentor required ➤ The Masters of Science in Clinical Research (MSCR) is a component of the KL2 program, but please note that <i>applications for the MSCR can also be submitted independently from the KL2 applications.</i> See below for additional details on the MSCR program.

Pediatric research applicants should contact stacy.heilman@emory.edu for pediatrics specific support and guidance.

INTRAMURAL/SEED/PILOT

Program/Link **Emory+Children's Pediatric Research Center Pilot Program**
www.pedsresearch.org/news/article/2012-center-pilot-rfa

Purpose The primary goal is to build new collaborations that will lead to sustainable multi-investigator research programs, new grants, and important new discoveries related to our pediatric mission in producing innovative advances in child health research. See the RFA at the link above for specific focus topics for each of these pediatric centers:

- Children's Center for Cardiovascular Biology
- Children's Center for Clinical Outcomes Research & Public Health (CORPH)
- Children's Center for Cystic Fibrosis Research
- Children's Center for Developmental Lung Biology
- Children's Center for Immunology and Vaccines
- Children's Center for Pediatric Healthcare Technology Innovation
- Children's Center for Pediatric Nanomedicine
- Children's Center for Neuroscience
- Children's Center for Transplant Immunology and Immune Therapeutics

Funds Avail Up to \$50K for one year
(exception for Nanomedicine pilots that may budget up to \$60K)

Deadline March 1, 2012

Remarks

- Proposals that link researchers in different areas of expertise and/or at different institutions are particularly encouraged
- At least one principal investigator must be a faculty member in the Department of Pediatrics at Emory or on the staff of Children's Healthcare of Atlanta

Program/Link **Healthcare Innovation Program/ACTSI Seed Grant**
<http://hip.emory.edu/documents/hip%20seed%20grant.pdf>

Purpose The Emory/Georgia Tech Healthcare Innovation Program (HIP), in partnership with the Atlanta Clinical and Translational Science Institute (ACTSI) and Children's Healthcare of Atlanta (CHOA), is pleased to invite research seed grant proposals in Healthcare Innovation. The seed grant program will fund multi-investigator, multi-disciplinary teams examining healthcare services and clinical effectiveness. Awards will support innovative approaches that address issues of healthcare quality, costs, and/or access that are consistent with the goals of the HIP and the ACTSI (see: <http://www.hip.emory.edu/about/mission/index.html>).

Topics: Two types of studies will be considered; health services research and clinical effectiveness research.

Funds Avail	Categories: Two categories of grants will be considered: Preliminary Study Grants - \$25K for one year max Complete Project Grants - \$25K/year for two years max
Deadline	LOI due February 15, 2012 Application due March 1, 2012 A letter of intent with the title of the project, the names of investigators, and the proposed total budget must be e-mailed no later than 2 weeks before submission to Maryam Carn, HIP Program Coordinator (maryam.carn@emory.edu).
Remarks	➤ Applications must include: ○ A minimum of two faculty investigators from different academic units (e.g., schools or departments) at Emory, Georgia Tech, and/or Morehouse School of Medicine ○ At least one medical or nursing staff member at Emory Healthcare, CHOA, Grady, and/or the Atlanta VAMC. The hospital staff member may be represented by one of the university faculty.

Program/Link	Georgia Research Alliance (GRA) VentureLab Commercialization Seed Award http://www.gra.org/LinkClick.aspx?fileticket=cY9RLH5A3g%3d&tabid=325
---------------------	---

Purpose	The Award is designed to identify universities technologies with commercial potential and move them into the commercialization process.
----------------	---

Eligibility for the Technology Commercialization Award program requires that the project meet certain criteria as described below:

1. *Focus:* The project must focus on technologies for the life sciences industry as broadly-defined. Examples include (but are not limited to): biologics, small molecule therapeutics, medical devices, imaging, diagnostics and health informatics.
2. *Commercial potential:* The project must have potential commercial utility. Projects requesting funding for research that would be considered basic or only for the sake of adding to knowledge in a certain field will not be considered. A business or commercialization plan for the project at this stage is not required.
3. *Potential for intellectual property protection:* The project should be based on or have the potential to generate technology for which intellectual property protection may be obtained. Intellectual property protection may be in the form of patent applications, issued patents, trade-secret information and copyrighted material.
4. *Scientific and technology merit.*
5. *Intent to pursue further development and commercialization:* The investigator or investigators should demonstrate an interest in and desire

to participate on the team responsible for pursuing commercialization of the project. Investigators are not expected to assume commercial management roles or responsibilities but rather to provide scientific direction in a team environment that includes individuals with relevant business experience.

6. *Potential for future funding* via SBIR, STTR grants, angel investors, strategic partners or venture capital.

Funds Avail Phase I: Up to \$50,000

Deadline April 5, 2012 by 5pm

Remarks ➤ Eligibility: The CFP is open to full-time research faculty and faculty of the professorial ranks (assistant, associate, or full) of all four year academic institutions in the state of Georgia and to full-time scientists of the U.S. Centers for Disease Control and Prevention who are based in Georgia.

Other Research Related Announcements

Master of Science in Clinical Research (MSCR) degree program

http://www.actsi.org/areas/retcd/mscr1/mscr_emory/application_instructions.html

The MSCR degree program provides didactic and mentored clinical and/or translational research training. Multiple faculty members in Pediatrics have benefited from this program and there are several avenues that one can go through this program.

- Traditional entry – cost to the participant is ~\$28,000 plus fees
- Using Emory Courtesy Scholarship alone – cost to the participant is ~\$14,000 plus fees (or extend the program over multiple years and use the Emory Courtesy Scholarship throughout for a cost of \$0)
- KL2 Award Recipients – will receive Emory Courtesy Scholarship AND ACTSI scholarship for a cost of \$0 to the participant
- ACTSI sponsored MSCR Scholarship – will receive Emory Courtesy Scholarship AND ACTSI scholarship for a cost of \$0 to the participant

Applications are now being accepted for classes beginning in August 2012. While there is a rolling admissions policy for the MSCR program, applicants are encouraged to apply soon in order to also apply for available scholarship funds.

To apply for the entire KL2 program, [see information above](#). For additional information and to apply for the ACTSI sponsored MSCR tuition scholarship, see additional information at the ACTSI RETCD website (www.actsi.org/retcd) and by contacting Cheryl Sroka, RETCD Program Administrator (csroka@emory.edu ; 404-727-5096).

Submit Research Ideas to Autism Speaks

[http://autismspeaks.ideascale.com/?utm_source=social-](http://autismspeaks.ideascale.com/?utm_source=social-media&utm_medium=email&utm_campaign=myresearchidea&msource=MyIdeaVideo)

[media&utm_medium=email&utm_campaign=myresearchidea&msource=MyIdeaVideo](http://autismspeaks.ideascale.com/?utm_source=social-media&utm_medium=email&utm_campaign=myresearchidea&msource=MyIdeaVideo)

“My Research Idea” is a campaign brought to you by Autism Speaks to allow you to provide

input into their review and prioritization of research priorities and goals for the years ahead.

Summer Research Opportunity for Medical & Graduate Students

Alex's Lemonade Stand Pediatric Oncology Student Training (POST) Program

www.ALSFgrants.org/post

Application deadline: March 15, 2012

The POST Program is designed to enable medical and graduate students to gain experience in the lab of an established researcher and exposure to the field of pediatric oncology over the summer months. A \$6000 grant is available to use for a minimum of 8 weeks between May 1 – Aug 31, 2012.

NIH STANDARD DUE DATES CITED ABOVE

	Cycle I	Cycle II	Cycle III
Mechanism(s)	Due Date	Due Date	Due Date
P Series ALL – new, renewal, resubmission, revision	25-Jan	25-May	25-Sept
R01 NEW <i>renewal, resubmission, revision</i>	5-Feb <i>5-Mar</i>	5-Jun <i>5-Jul</i>	5-Oct <i>5-Nov</i>
R41, R42, R43, R44, U43, U44, <i>All - new, renewal, resubmission, revision</i>	5-April	5-Aug	5-Dec
R03, R21, R34 NEW <i>renewal, resubmission, revision</i>	16-Feb <i>16-Mar</i>	16-Jun <i>16-Jul</i>	16-Oct <i>16-Nov</i>
K series NEW <i>renewal, resubmission, revision</i>	12-Feb <i>12-Mar</i>	12-Jun <i>12-Jul</i>	12-Oct <i>12-Nov</i>
All AIDS and AIDS-Related Applications (for mechanisms cited above) <i>All - new, renewal, resubmission, revision</i>	7-May	7-Sept	7-Jan

For the full schedule of NIH standard due dates, see

<http://grants1.nih.gov/grants/funding/submissionschedule.htm>



ABOUT THE BIRD:

This compilation of general interest funding opportunities and announcements with possible collaborative potential is distributed to our pediatric research community monthly. It is compiled by the Emory-Children's Pediatric Research Center to disseminate funding announcements of potential interest in a consolidated manner. More specific announcements are distributed in a more targeted fashion.

If you are not receiving this directly from Stacy Heilman and wish to be added to our Pediatric Research listserv, please e-mail stacy.heilman@emory.edu to make the request. Please also contact Stacy if you are interested in applying for any pediatric focused research funding opportunities and/or if you are interested in building collaborative efforts and programs towards applying for future pediatric research funding.